Impact of 2023 Updated IDSA Guidelines on Antimicrobial Resistant Gram-Negative Infection Treatment

Opinion
Video

Dr Christian Sandrock evaluates the impact of 2023 updated IDSA guidelines on treatment decisions for patients with antimicrobial resistant gram-negative infections and for patients with multidrug-resistant pathogens.

Recent Videos
Related Content
Investigational cUTI Antibiotic Meets Endpoint, Phase 3 Study Stopped Early

Investigational cUTI Antibiotic Meets Endpoint, Phase 3 Study Stopped Early

John Parkinson
May 28th 2025
Article
Can Diagnostics Aid in Alleviating Antimicrobial Resistance and Sepsis?

Can Diagnostics Aid in Alleviating Antimicrobial Resistance and Sepsis?

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc
May 16th 2025
Podcast
Ceftobiprole Launches Commercially in US

Ceftobiprole Launches Commercially in US

John Parkinson
May 20th 2025
Article
From Pathogen to Infectious Disease Diagnosis: Test Determines Between Bacterial and Viral Infections in 15 Minutes

From Pathogen to Infectious Disease Diagnosis: Test Determines Between Bacterial and Viral Infections in 15 Minutes

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc ;Eran Eden, PhD
April 14th 2025
Podcast
Greater Incidence of Antimicrobial-Resistant Infections in Outpatients With Cancer

Greater Incidence of Antimicrobial-Resistant Infections in Outpatients With Cancer

John Parkinson
May 13th 2025
Article
Over 1 Million Drug-Resistant Infections Went Untreated Across LMICs

Over 1 Million Drug-Resistant Infections Went Untreated Across LMICs

Sophia Abene
May 8th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.